3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
8
Gastrointestinal
2
Thoracic
1
Genitourinary
1
Dermatologic
1
Conditions
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
2
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
27
Docetaxel
20
Cyclophosphamide
18
Surveys and Questionnaires
15
Therapeutics
14
Radiotherapy
13
Paclitaxel
12
Psychiatric Rehabilitation
11
Early Intervention, Educational
11
Carboplatin
11
Standard of Care
10
olaparib
9
Zoledronic Acid
9
Specimen Handling
9
Radiosurgery
9
Magnetic Resonance Spectroscopy
9
Interviews as Topic
9
Gemcitabine
9
Trastuzumab
8
Methods
8
Fulvestrant
8
palbociclib
7
fludarabine
7
durvalumab
7
Taxes
7
Nivolumab
7
Fluorodeoxyglucose F18
7
Flow Cytometry
7
Educational Status
7
Blood Specimen Collection
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Sevoflurane
×
Genitourinary
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled